MIRM vs TVTX
MIRM: Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative, minimally-absorbed therapies for rare cholestatic liver diseases. TVTX: A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need.
Side-by-side fundamentals
| Metric | MIRM | TVTX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $83.44 | $52.58 | |
| Market cap | $5.4B | $5.0B | |
| Net margin FY2025, SEC XBRL | -4.5% | -5.2% | MIRM higher |
| Operating margin FY2025, SEC XBRL | -4.2% | -12.8% | MIRM higher |
| ROE FY2025, SEC XBRL | n/a | -22.2% | |
| ROA FY2025, SEC XBRL | -2.8% | -4.2% | MIRM higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +54.7% | +110.5% | TVTX higher |
| Revenue CAGR (3y) SEC XBRL | +89.1% | +64.9% | MIRM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.86 | 1.19 | |
| 1-year return as of 2026-10-21 close | +21.0% | +89.1% | TVTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.